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Abstract 
BACKGROUND: Cancer is a deadly malignant disease and is prevalent in Sub Saharan Africa. The North East 
part of Nigeria in particular and the country, in general, are struggling to cope with the increasing burden of cancer 
and other communicable and non-communicable diseases. The situation is worsened by the ongoing insurgency 
and terrorist activities in the area. 
AIM: The aim of this paper is to present the research findings from a cohort study aimed at the analysis of the 
estimation of the survivorship time of the real data of cancer patients in the North-eastern part of Nigeria and to 
establish if the insurgency in the region has contributed negatively to the life expectancy of its inhabitants. 
MATERIAL AND METHODS: The record of 1,090 patients from medical records departments of the University of 
Maiduguri Teaching Hospital (UMTH), located in Maiduguri, the capital city of Borno State in northeast Nigeria 
was obtained. The record showed patients that were diagnosed and died of one type of cancer or the other from 
2004 to 2017. All the cancer cases included in the present study were grouped into sex, age, marital status, 
occupation, date admitted and date of death/discharge. Descriptive statistics and Kaplan-Meier method were used 
to analyse the data using SPSS version 23 while Microsoft EXCEL and Minitab 16.0 were used for data cleansing 
and organisation. 
RESULTS: Of the 1,090 patients analysed, 920 (84.40%) experienced the event, i.e. death, while 170 (15.60%) 
patients were censored. The data were analysed based on the ages and sex of the patients. 50.20% of the 
patients were of ages 21-50 years. The proportions of patients in this age bracket surviving past 7 days are 75%, 
while those between ages 80 years and above is 12 days. Others are of survival time of 5 days (ages 0-20 years) 
and 7 days (51-79 years). Using sex, 75% of the patients’ survival time is 7 days in the case of male and 6 days 
for females. It is safe to say that the survival time for cancer patients of the university the Maiduguri is 6 days and 
the result reflects the Northeastern part of Nigeria. This is because the hospital is one of few tertiary healthcare 
facilities in that area and consequently, cancer cases are often referred there. 
CONCLUSION: Cancer incidence is high, and the probability of survival reduces as the survival time increases. 
This is a dire situation in need of urgent intervention from the government, groups and individuals to tackle the 
scourge of cancer, thereby improving on the life expectancy battered by the ongoing Boko Haram insurgency in 
that region. 
 
 
Introduction 
 
Sub Saharan Africa is one of the areas that 
plagued with the prevalence of non-communicable 
diseases, especially cancers which is on the increase. 
Cancer of any type is the most common and lethal 
malignancies in developing countries like Nigeria. 
Cancer is an unwelcome guest in every home, and it 
is seen as a death sentence in Nigeria. Northeast 
Nigeria is one of the least developed areas of the 
country, lagging dangerously behind in virtually every 
development index. The region is notoriously 
staggering under the weights of poverty [1], 
insurgency and terrorism [2], [3], [4], hunger and low 
life expectancy [5], polio, maternal and child mortality 
[6], [7] and so on.   
Cancer is not only prevalent in the North East, 
Nigeria [8], [9], but to the entire country which are 
battling to cope with other health challenges such as 
mental health [10], [11], maternal and child health 
[12], [13] and HIV AIDS [14]. The high case fatality 
rate of cancer in Nigeria is due to low level of cancer 
awareness and screening, late discovery, unhealthy 
lifestyle, superstitious beliefs, limited or poorly funded 
healthcare facilities, the dearth of experts in oncology 
and others to mention but a few.  
A patient’s journey along a disease pathway 
can be highly complex and can be impacted by 
recurrences, co-morbidities, and interventions, to 
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name a few. Cancer as one of the world’s best killer 
disease, for example, has killed many and left only a 
few to tell the tale. To disentangle the complexities, 
we need special kinds of survival models. These 
enable us to investigate diverse aspects of disease 
aetiology and explore the impact of risk factors at all 
stages. Crucially, we can then attempt to 
communicate risk profiles in many ways, 
understandable to both patient and clinician, through 
easily interpretable measures (such as the impact on 
life expectancy, postponable deaths, survival and 
transition probabilities). The study of survival of 
cancer patients will be an immense contribution to the 
fight against the dreaded disease. 
Regard to sound statistical practice, in 
particular, the use of statistical approaches that 
provide clinically and peer-reviewed relevant 
information, will help maximise the potential of 
molecular markers for the care of cancer patients. 
Kaplan-Meier (K-M) method otherwise known as the 
product limit method is a statistical technique used to 
analyse cancer data. It is applied in analyzing the 
distribution of the patient's survival times following 
their recruitment into the study. The analysis 
expresses this in terms of the proportion of patients 
still alive up to a given time t, following the recruitment 
or entry into the study. 
This paper aims to present the research 
findings from a cohort study focused at the analysis of 
the estimation of the survivorship time of the real data 
of cancer patients in the North-eastern part of Nigeria 
and to establish if the insurgency in the region has 
contributed negatively to the life expectancy of its 
inhabitants. Also, the result that established the 
observed relationship between survival time and 
survival probability is presented. Kaplan-Meier method 
was used in the survival data analysis of the cancer 
data, and the findings were discussed extensively.  
 
 
Material and Methods 
 
Data Collection 
The record of 1,090 patients from medical 
records departments of the University of Maiduguri 
Teaching Hospital (UMTH), located in Maiduguri, the 
capital city of Borno State in northeast Nigeria was 
obtained.  
The record showed patients that were 
diagnosed and died of one type of cancer or the other 
from 2004 to 2017. All the cancer cases included in 
the present study were grouped into sex, age, marital 
status, occupation, date admitted and date of 
death/discharge. 
 In survival analysis, follow up periods are 
calculated from when subjects were enrolled in the 
study (i.e. date admitted). 
Research on cancer is often very interesting 
because of the high fatality rate of the disease is 
diagnosed later and or untreated. One of the methods 
used in the survival analysis in oncology and 
epidemiology studies is the Kaplan-Meier method (K-
M) [15], [16], [17], [18], [19], [20], [21], [22], [23], [24]. 
K-M method is usually used in conjunction with Cox 
proportional hazard regression, immunohisto-
chemistry, lognormal, hazard ratio, Chi-squared test, 
log-rank test and so on. 
A summary of the use of the K-M method in 
conjunction with other statistical methods is given in 
Table 1.  
Table 1: Kaplan-Meier and other statistical methods used in the 
survival analysis of different types of cancer 
Type of Cancer Statistical methods Cases 
investigated 
Author 
Breast KM, Chi-squared test, Cox 
regression 
207 [25] 
Breast KM, Cox regression 300 [26] 
Breast KM, Cox regression 135 [27] 
Gastric KM 179 [28] 
Breast KM 308 [29] 
Breast KM, Cox regression 139 [30] 
Leukemia KM, Cox regression 527 [31] 
Ovarian KM 81 [32] 
Rectal KM, Cox regression 3786 [33] 
Liver KM, Cox regression 30,954 [34] 
Thyroid KM, Cox regression 12,128 [35] 
Gastric KM, Chi-squared test, Cox 
regression 
4596 [36] 
Breast KM, Cox regression 1391 [37] 
Breast KM, Hazard ratio 10 226 [38] 
Prostate KM, Cox regression 579,608 [39] 
kin KM, Cox regression, Log-rank test 83 [40] 
 
Data Preparation 
In preparing the data for Kaplan-Meier 
survival analysis, each subject (patient) of the data 
component is mainly characterized by 3 variables: 1) 
their serial time (in days or years); 2) their status at 
the end of their serial time (event occurrence or 
censored); and 3) the study group or stage they are 
in.  
For the computation of survival time curves 
and probabilities, the serial times for the patients are 
arranged from the shortest to the longest without 
regards to when they are recruited into the study as 
long as left censorship is not encountered. By this 
move, it can be ensured that all subjects within the 
group or stage begin the analysis at the same point 
and all are surviving independently until (event or 
censor) occurs.  
 
Reasons for adopting the K-M method 
The methodology is adopted for the following 
reasons. Firstly, the main target is to estimate a 
population survival curve from the sample obtained 
from the teaching hospital. Secondly, if every subject 
(patient) is followed until death, the curve may be 
estimated simply by computing the fraction surviving 
at each time t. Lastly, Kaplan-Meier curves have 
gravitated characteristics, which perhaps explains 
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their wide applicability in medical research as they 
provide a pictorial depiction of all the raw data, the 
failure times and the censoring times; yet they also 
provide a mathematical estimate of the given survival 
model.  
It is glad to note that the data presented in 
this article did not violate the six assumptions of the K-
M method. The assumptions are stated as follows:  1) 
The data is composed of two mutually exclusive and 
exhaustive states known as an event or censored; 2) 
The survival time was clearly defined and accurately 
measured; 3) The data is right censored; 4) The 
censoring and the event are independent. This is vital 
since the efficiency of the K-M method depends on 
the analysis of observed data; 5) No trend was 
observed in the data; 6) Right censoring is similar in 
all the groups (sex and age). 
     
 Data Processing    
Raw data are stored in MS EXCEL format 
using actual calendar date and time. During analysis, 
serial time may be automatically calculated, and this is 
used in curve construction and data analysis. The first 
step in the preparation of K-M analysis involves the 
construction of a table using Minitab or Excel 
spreadsheet or in SPSS containing the three key 
elements required for input. These are: 1) serial time, 
2) status at serial time (1 = Alive, 0 = Death) and 3) 
age group. 
 
 
Results 
 
These were performed using SPSS version 
23.0. Data were reported by sex, age, marital status, 
occupation, date of admission and date of 
death/discharge. A descriptive analysis of the data 
was carried out, and each character was described by 
frequencies and percentages. Kaplan-Meier analyses 
were conducted to mainly estimate overall survival 
rates of the various types of cancer. The survival time 
of a patient is referred to the number of months or 
days (duration) from the date of diagnosis of cancer to 
the date of the patient died or last contact (censored) 
or the date of the end of the study for patients who 
were still alive or date of loss to follow-up (censored). 
The differences in survival between the stages were 
compared by the log-rank test. A two-tailed p-value of 
< 0.05 was considered as statistically significant. 
 
Descriptive Statistics 
Data on 1,090 cancer cases were gathered of 
which 478 (43.9%) were male, while 612 (56.10%) 
were female, shown in Table 2.  
 
Table 2: The sex distribution of the patients 
Sex Frequency Per cent Cumulative Percent 
Male 478 43.9 43.9 
Female 612 56.1 100.0 
Total 1090 100.0  
 
From Table 3, it can be seen that 50.20% of 
the patients were between the ages of 21-50 years 
old, 17.70% were of ages below 20 years old, 29.9% 
were between ages 51-79 years while 1.9% were 80 
years and above.  
Table 3: The age distribution of the patients  
  Age Frequency Percent Cumulative Percent 
Valid 0-20 193 17.7 17.8 
21-50 547 50.2 68.1 
51-79 326 29.9 98.1 
80 & Above 21 1.9 100 
Total 1087 99.7  
Missing  3 0.3  
Total 1090 100  
 
A group of 227 (20.8%) of the patients are 
single, 832 (76.3%) are married, 12 (1.1%) are 
widowed, and 19 (1.7%) are missing values, shown in 
Table 4.  
Table 4: Marital status of the patients 
Marital status Frequency Per cent 
Single 227 20.8 
Married 832 76.3 
Widow/Widower 12 1.1 
Missing 19 1.7 
Total 1090 100 
 
Of the 478 females, 40.1% were housewives. 
10.8% of the patients were children while 13.9% were 
civil servants. The details of the other occupation are 
given in Table 5.  
Table 5: the Recorded occupation of the patients 
 Occupation Frequency Percent Cumulative Percent 
Valid Applicant 12 1.1 1.1 
 Soldier 4 0.4 1.5 
 Banker 1 0.1 1.6 
 Bricklayer 1 0.1 1.7 
 Business Man 71 6.5 8.4 
 Butcher 1 0.1 8.5 
 Civil Servant 151 13.9 22.7 
 Caterer 1 0.1 22.7 
 Cattle Rearer 5 0.5 23.2 
 Child 118 10.8 34.3 
 Clergy 1 0.1 34.4 
 Contractor 1 0.1 34.5 
 Police Officer 4 0.4 34.9 
 Driver 11 1 35.9 
 Politician 3 0.3 36.2 
 Farmer 97 8.9 45.3 
 Retired 19 1.7 47.1 
 Fisherman 2 0.2 47.3 
 Scholar 5 0.5 47.7 
 House Wife 437 40.1 88.8 
 Security Man 4 0.4 89.2 
 Mechanic 2 0.2 89.4 
 Student 85 7.8 97.4 
 Tailor 5 0.5 97.8 
 Teacher 8 0.7 98.6 
 Technician 2 0.2 98.8 
 Widow/Widower 13 1.2 100 
 Total 1064 97.6  
Missing System 26 2.4  
Total  1090 100  
 
 
The weird occupations seen in Table 5 can be 
attributed to high illiteracy of the patients and poor 
record keeping by the staff of the hospital. Finally, it 
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can be seen from Table 6, that 170 (15.6%) were alive 
and 920 (84.4%) were dead after admission in the 
hospital.  
Table 6: End status of the patients 
Status Frequency Per cent Cumulative Percent 
Dead 920 84.4 84.4 
Alive 170 15.6 100 
Total 1090 100  
 
 
Kaplan-Meier Results 
The data presented in this subsection are 
from the K-M analysis. These are given as: case 
summary for age (Table 7), case summary for sex 
(Table 8), means and medians for survival time for 
age (Table 9), means and medians for survival time 
for sex (Table 10), overall comparison tests for the 
age (Table 11) and overall comparison tests for the 
age (Table 12). 
Table 7: Case processing summary for age 
Age Total N N of Events 
Censored 
N Per cent 
0-20 193 150 43 22.30% 
21-50 547 473 74 13.50% 
51-79 326 274 52 16.00% 
80 & Above 21 20 1 4.80% 
Overall 1087 917 170 15.60% 
 
Table 7 displays the age of the cancer 
patients (categorised into age groups from 0-20 years, 
21-50 years, 51-79 years and 80 years and above), 
the total number of patients in each age group, 
number of patients experienced events, and censored 
patients. Age 0-20 years has a total number of 193 
patients with 150 been number of events and 43 
(22.3%) as censored patients, age 21-50 has a total 
number of 547 patients with 473 patients that have 
experienced the event and 74 (13.5%) as censored 
patients, age 51-79 has a total number of 326 patients 
with 274 patients that have experienced the event and 
52 (16.0%) as censored patients and age 80 and 
above has a total number of 21 patients with 20 total 
number of events and 1 (4.8%). It was noted that age 
group 21-50 has the highest number of events 
followed by 51-79 and age group 80 and above with 
the lowest number of events. 
Table 8: Case processing summary for sex 
Sex Total N N of Events 
Censored 
N Per cent 
Male 478 401 77 16.10% 
Female 612 519 93 15.20% 
Overall 1090 920 170 15.60% 
 
Table 8 displays the sex of patients 
diagnosed with cancer, the total number of patients for 
each sex group, number of patients experienced 
events, and censored patients. Four hundred seventy-
eight male patients were admitted with 401 been 
number of events and 77 (16.1%) as censored 
patients while there were a total of 612 females with 
519 patients that have experienced the event and 93 
(15.2%) as censored patients Clearly, the male 
patients have the lowest number of events. 
Table 9: Means and medians for survival time for age 
AGE 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
0-20 26.035 3.225 19.715 32.356 14 1.949 10.18 17.82 
21-50 30.89 2.414 26.159 35.622 16 1.488 13.084 18.916 
51-79 35.808 4.234 27.509 44.107 19 1.182 16.683 21.317 
80 & 
Above 
29.651 6.487 16.936 42.366 20 4.577 11.028 28.972 
Overall 31.41 1.839 27.807 35.014 17 0.864 15.306 18.694 
 
Table 9 gives a quick quantitative comparison 
of the typical survival times to effect for each of the 
age groups. The median survival time is calculated as 
the smallest amount of survival time for which the 
survivor function is less than or equal to 0.5.  
The overall median survival time (i.e. the time 
at which the survival probability is 50% or 0.5) is 31 
days. In other words, for cancer patients in the North, 
the chance of living beyond 31 days is 50%. The 
median survival time for ages 0-20 was 26 days, 30 
days for ages 21-50, 35 days for age 51-79 and ages 
80 and above was 29 days. These clearly show that 
the chance of living beyond 26 days, 30, 35 and 29 for 
ages 0-20, 21-50, 51-70 and above 80 years 
respectively after being admitted/diagnosed with the 
disease is 50%.  
It can be seen that the higher the estimated 
mean time, the greater the chances of survival. This 
goes to show that ages 51-79 has the highest chance 
of survival while ages 0-20 years has the least chance 
of survival.  
The log-rank test can be applied if the 
confidence limits do not overlap between the given 
levels. Clearly, from Table 9, there is no overlap 
between ages in the confidence intervals; hence 
differences in effect on time to an event can be 
inferred using the log-rank test. 
Table 10: Means and medians for survival time for sex 
Sex 
Mean Median 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Male 32.947 2.984 27.099 38.795 19 1.236 16.578 21.422 
Female 30.184 2.286 25.703 34.665 16 1.33 13.394 18.606 
Overall 31.355 1.833 27.762 34.948 17 0.852 15.331 18.669 
 
From Table 10, it can be seen that the 
estimated mean time until death is 32 days for male, 
30 days for females, which shows that females have a 
slightly increased chance of survival than males. 
The median survival time for a male is 19 
days while that of females is 16 days. These clearly 
show that the chance of living beyond 19 and 16 days 
for males and females, respectively for cancer 
patients in the Northeastern part of Nigeria is 0.5 after 
being diagnosed with the disease. 
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Clearly, from Table 10, there is a lot of 
overlap in the confidence intervals; hence it is unlikely 
that there is much difference in the average survival 
time. 
Table 11: Overall Comparison Tests for the age 
Test of equality Chi-Square Df Sig. 
Log Rank (Mantel-Cox) 3.812 3 0.283 
Breslow (Generalized Wilcoxon) 6.845 3 0.077 
Tarone-Ware 5.622 3 0.131 
 
Table 11 is the test of equality of survival 
distributions for the different levels of age. The 
significance values of the tests (0.283, 0.077, 0.131) 
are all greater than 0.05. The interpretation of this is 
the acceptance of the null hypothesis means that 
there is no significant evidence of a difference in the 
observed survival times for the categories of age 
considered.  
Table 12: Overall Comparison Tests for the sex 
Test of equality Chi-Square Df Sig. 
Log Rank (Mantel-Cox) 1.440 1 0.230 
Breslow (Generalized Wilcoxon) 3.573 1 0.059 
Tarone-Ware 2.814 1 0.093 
  
Table 12 is the test of equality of survival 
distributions for the different levels of sex. It shows 
that the significance values of the tests (0.230, 0.059 
and 0.093) are all greater than 0.05. The interpretation 
of this is the acceptance of the null hypothesis implies 
that there is no significant evidence of a difference in 
the observed survival times for the categories of age 
considered.  
Although, females have a slightly increased 
chance of survival even though, as inferred from the 
log-rank test, sex is not a barrier to death. 
 
Plots of the Survival Functions and 
survival probability estimation 
The survival curves (Figures 1 and 2) give a 
visual depiction of the life tables, the horizontal axis 
represents the time to the event, and the vertical axis 
shows the estimated probability of survival. 
 
Figure 1: Kaplan-Meier survival plot for the ages 
In this plot, drops in the survival curve occur 
whenever the patients experience the event  
 Also, the summary of survival probability 
estimate with the survival time for the age and sex are 
presented in Table 13 and 14 respectively.  
 
Figure 2: Kaplan-Meier survival plot for the sex 
 
From Table 13, the proportion of subjects or 
patients surviving past 5 days is 75%, the proportion 
of subjects or patients surviving past 14 days is 50% 
and the proportion of subjects or patients surviving 
past 32 days is 25% for age 0-20 years. 
Table 13: Survival probability estimate with the survival time 
for age 
Age 
25 50 75 
Estimate Std. Error Estimate Std. Error Estimate Std. Error 
0-20 32 4.755 14 1.949 5 0.915 
21-50 35 2.56 16 1.488 6 0.561 
51-79 40 3.279 19 1.182 7 0.97 
80 & 
Above 
34 4.799 20 4.577 12 2.588 
Overall 35 1.815 17 0.864 6 0.443 
Note; Survival time is given in days (D). This can easily be seen in Figure 1. 
 
The proportion of subjects or patients 
surviving past 6days is 75% and the proportion of 
subjects or patients surviving past 16 days (which is 
the median survival time) is 50% and the proportion of 
subjects or patients surviving past 35 days is 25% for 
age 21-50 years. 
The proportion of subjects or patients 
surviving past 7 days is 75%, the proportion of 
subjects or patients’ surviving past 19 days is 50% 
and the proportion of subjects or patients surviving 
past 40 days is 25% for age 51-79 years. 
The proportion of subjects or patients 
surviving past 12 days is 75%, the proportion of 
subjects or patients surviving past 20 days is 50% and 
the proportion of subjects or patients surviving past 34 
days is 25% for ages 80 years and above. 
From this analysis, the probability of survival 
reduces as the survival time increases. 
From Table 14, the proportion of subjects or 
patients surviving past 7 days is 75%, the proportion 
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of subjects or patients’ surviving past 19 days is 50% 
and the proportion of subjects or patients surviving 
past 39 days is 25% for Males. 
Table 14: Survival probability estimate with the survival time 
for sex 
Sex 
25% Estimate 50% Estimate 75% Estimate 
Estimate 
(days) 
Std. Error 
Estimate 
(days) 
Std. Error 
Estimate 
(days) 
Std. Error 
Male 39 2.69 19 1.236 7 0.829 
Female 32 2.048 16 1.33 6 0.52 
Overall 35 1.816 17 0.852 6 0.44 
Note; Survival time is given in days (D). This can easily be seen in Figure 2. 
 
The proportion of subjects or patients 
surviving past 6days is 75% and the proportion of 
subjects or patients surviving past 16 days (which is 
the median survival time) is 50% and the proportion of 
subjects surviving past 32 days is 25% for Females. 
Also, from this analysis, the probability of 
survival reduces as the survival time increases. 
 
 
Discussion 
 
A good glance at the results shows most 
patients died the same day or few days to date of 
admission. Hence, it was not a surprise that the 
analysis shows overall survival time of 6 days for 75% 
of patients with cancer at the University Teaching 
Hospital, Maiduguri. This is a far-cry to survival data 
obtained in another part of the country. The study 
shows that over 84% of the cancer cases died. We 
have more of the cases for women than for men. Over 
40% of the cases for female were those who reported 
their occupation as housewives. Over 50% of the 
cases were age 21-50 years old. Only 1.9% of the 
cases were of ages 80years and above. 
Following the result of the research, it is 
obvious that we have a major problem with the 
management of cancer in the region under review and 
Nigeria in general. The reasons for this might not be a 
difference of the below points. 
The Northeast part of Nigeria is one of the 
poorest parts of Nigeria. Years of corruption and lack 
of investment in the health facilities have contributed 
to a near collapse of the health facilities of the region 
in particular and Nigeria in general. Poverty, illiteracy 
and superstition are contributory factors why diseases 
like cancer are endemic in the area. This is 
exacerbated by the ongoing Boko Haram insurgency 
and herdsman attacks. The insurgency has added to 
the already strain on the few available health facilities 
in the area and drastically reduction to access to 
health care. The effect is not limited to cancer, but 
other illness such as HIV AIDS epidemic, a cholera 
outbreak and others. It can be noted that the 
University of Maiduguri teaching is the only major 
tertiary health facility that covers Borno, Yobe, Gombe 
and Taraba states, an area and population that is 
greater than London, United Kingdom.  
The precarious political and social factors are 
drivers to the culture of patients reporting of their 
cases very late. Most cancers have different stages, 
one, two, three and four. While stage one and two can 
achieve a cure, stage three and four are usually 
advanced where you no longer talk about radical 
treatment but palliative treatment to see how you can 
prolong the patient’s life and improve the quality of 
life. The data for this research did not include the 
stage of cancer upon admission at the hospital, we 
suggest most cases to be at stage three and four 
going by the time to the event. 
Most patients do not go for screening; they 
mostly consult roadside chemists, extreme cases 
among the people approach churches, Muslim clerics 
and herbalist. 
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